SGHT (Sight Sciences) Growth Rank: 8 (As of Aug. 14, 2026) — 14% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGHT Sight Sciences Inc SGHT
64 GF Score
Price $8.14
GF Value $4.62
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sight Sciences Growth Rank?

Sight Sciences SGHT -1.93% 64 Growth Rank is 8 as of Aug. 14, 2026, which is 14% above its 10-year median of 7.00. GuruFocus rates SGHT with a GF Score™ of 64/100 and a GF Value™ of $4.62 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Sight Sciences has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Sight Sciences Growth Rank Related Terms


SGHT vs TMCI, TLSI, SENS: Growth Rank Comparison

For the Medical Devices subindustry, Sight Sciences's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Growth Rank falls into.


SGHT
64GF Score
Sight Sciences Inc SGHT
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
Sight Sciences (SGHT) has a Growth Rank of 8 as of Aug. 14, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sight Sciences and its competitors. This is 14% above median its historical median of 7.00. Over the past decade, Sight Sciences' Growth Rank has ranged from 4.00 to 8.00.
Is Sight Sciences' Growth Rank too high?
Sight Sciences' current Growth Rank of 8 is 14% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. Overall, Sight Sciences has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Growth Rank compare to TMCI and TLSI?
Sight Sciences' Growth Rank of 8 can be compared against companies in the Medical Devices & Instruments industry. Historically, Sight Sciences' own Growth Rank has ranged from 4.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sight Sciences and its competitors. Sight Sciences's current Growth Rank is 8, which is 14% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.62, compared to a current price of $8.14 — trading 76.1% above its estimated fair value. The current Growth Rank is 8, which is 14% above median its 10-year median of 7.00. Sight Sciences' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Growth Rank is 8 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $8.14 is trading 76.1% above its estimated GF Value™ of $4.62. GuruFocus considers Sight Sciences to be Significantly Overvalued.

Key valuation signals for SGHT:

  • Growth Rank: 8 (14% above median its 10-year median of 7.00)
  • GF Value™: $4.62 vs. price of $8.14 (76.1% above fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
64GF Score

Get the complete analysis for SGHT

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.14
Price
$4.62
GF Value